




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61B 5/02	A1	(11) International Publication Number: WO 91/11137 (43) International Publication Date: 8 August 1991 (08.08.91)
<p>(21) International Application Number: PCT/US90/00518</p> <p>(22) International Filing Date: 30 January 1990 (30.01.90)</p> <p>(71) Applicant: MEDICAL PHYSICS [US/US]; P.O. Box 17471, Salt Lake City, UT 84117 (US).</p> <p>(72) Inventors: CLARK, Justin, S. ; 5055 Boabab Drive, Salt Lake City, UT 84117 (US). WALLACE, William, Dean ; 7043 South 300 West, Midvale, UT 84047 (US).</p> <p>(74) Agents: CLAYTON, Grant, R. et al.; Thorpe, North & Western, 9035 South 700 East, Suite 200, Sandy, UT 84070 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published With international search report.</p>

(54) Title: ENHANCED ARTERIAL OXYGEN SATURATION DETERMINATION AND ARTERIAL BLOOD PRESSURE MONITORING



(57) Abstract

A noninvasive system and method for monitoring arterial oxygen saturation levels and blood pressure. The apparatus includes a read LED (54) and an infrared LED (56) which are positioned to direct their respective light beams into, or reflected by a patient's body part. A phototransducer device (64) is positioned to receive the light beams (60, 62) which are transmitted through the body part. A pressure cuff (34) surrounds the body part (36) and the LEDs (54, 56). During calibration periods, pressure is applied to the body part (36) and the systolic and mean blood pressures and the arterial oxygen saturation level are determined. The pressure is then released from the body part (36) and another arterial oxygen saturation level is determined and the difference between the two oxygen saturation levels is used as a calibration factor during later monitoring periods to remove the effect of non-arterial oxygen saturation levels on the values obtained during the subsequent monitoring period.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

1

Enhanced Arterial Oxygen Saturation Determination and Arterial Blood Pressure Monitoring

BACKGROUND

5

1. The Field of the Invention

The present invention is related to noninvasive systems and methods which are used to monitor the physiological condition of a patient's circulatory system. More particularly, the present invention is related to an enhanced noninvasive system and method for monitoring a patient's arterial oxygen saturation, and which also provides continuous measurement of blood pressure.

15 2. The Background Art

The proper utilization of many lifesaving medical techniques and treatments depends upon the attending physician obtaining accurate and continually updated information regarding various bodily functions of the patient. Perhaps the most critical information to be obtained by a physician, and that which will often tell the physician a great deal concerning what course of treatment should be immediately instituted, are heart rate, blood pressure, and arterial oxygen saturation.

25 In settings such as operating rooms and in intensive care units, monitoring and recording these indicators of bodily functions is particularly important. For example, when an anesthetized patient undergoes surgery, it is generally the anesthesiologist's role to monitor the general condition of the patient while the surgeon proceeds with his tasks. If the anesthesiologist has knowledge of the patient's arterial oxygen saturation, heart rate, and blood pressure, the general condition of the patient's circulatory system can be assessed.

35

-2-

1 Arterial oxygen saturation (abbreviated herein as S_aO_2)
is expressed as a percentage of the total hemoglobin in the
patient's blood which is bound to oxygen. The hemoglobin
which is bound to oxygen is referred to as oxyhemoglobin.
5 In a healthy patient, the S_aO_2 value is above 95% since
blood traveling through the arteries has just passed
through the lungs and has been oxygenated. As blood
courses through the capillaries, oxygen is off-loaded into
the tissues and carbon dioxide is on-loaded into the
10 hemoglobin. Thus, the oxygen saturation levels in the
capillaries (abbreviated herein as S_cO_2) is lower than in
the arteries. Furthermore, the blood oxygen saturation
levels in the veins is even lower, being about 75% in
healthy patients.

15 Importantly, if the patient's arterial oxygen saturation
level is too high or too low, the physician may take action
such as reducing or increasing the amount of oxygen being
administered to the patient. Proper management of S_aO_2 is
particularly important in neonates where S_aO_2 must be
20 maintained high enough to support cell metabolism but low
enough to avoid damaging oxygen-sensitive cells in the eye
and causing impairment or complete loss of vision.

Blood pressure monitoring includes at least three values
which are of interest to a physician. First, the systolic
25 pressure is the high pressure generated in the arteries
during contraction (or systole) of the left ventricle of
the heart. Second, the diastolic pressure is the pressure
maintained in the arteries during relaxation (or diastole)
of the left ventricle. Due to the elastic nature of the
30 walls of the arteries, the diastolic pressure is above zero
but less than the systolic pressure.

A third value of interest to a physician is the mean
arterial pressure. The mean arterial pressure may be
simply described as the arithmetic average of all the blood
35

-3-

1 pressure values between, and including, the systolic and
diastolic pressures. In addition to the just mentioned
three discrete blood pressure values, a physician is also
5 interested in obtaining the blood pressure waveform. As is
well known, patients having identical systolic and
diastolic values may have very different mean arterial
pressures and their blood pressure waveforms may be
dramatically different. Having the blood pressure waveform
at hand allows the physician to more accurately assess the
10 patient's condition.

Blood pressure is generally measured quantitatively in
millimeters of mercury (mmHg) referenced against
atmospheric pressure (about 760 mmHg). Thus, in a normal
15 person the blood pressure may be 120 mmHg above atmospheric
pressure during systole and 70 mmHg above atmospheric
pressure during diastole. Such values are commonly recorded
as "120 over 70" (120/70).

Continuous monitoring of arterial oxygen saturation
levels (S_aO_2) and arterial blood pressures each present
20 unique problems.

One method of determining S_aO_2 is to withdraw blood from
an artery and analyze the same to determine the amount of
oxyhemoglobin present. While in vitro analysis provides
the most accurate blood gas determinations, the
25 disadvantages of drawing a blood sample each time an S_aO_2
determination is desired by the physician is readily
apparent. Significantly, even in the operating room in
vitro S_aO_2 determinations may take up to several minutes.
Since nerve cells deprived of sufficient oxygen begin to
30 die in a matter of minutes, the time taken to obtain the
results of an in vitro S_aO_2 analysis may seriously
compromise patient safety.

Particularly in the case of a patient undergoing routine
surgery, the difficulties of withdrawing blood samples
35

1 throughout the surgical procedure for S_aO_2 determinations is
generally too great to be adopted as a general practice.
Still, monitoring of S_aO_2 during all surgeries where general
anesthesia is used and in intensive care units is expected
5 to have a significant positive effect on the well-being of
patients. Thus, past efforts have been directed to
providing noninvasive systems and methods for determining
arterial S_aO_2 .

10 The term "oximetry" has been adopted in the art to refer
to noninvasive apparatus and methods for determining blood
oxygen saturation levels. Previously available oximetry
systems make use of the fact that the absorption
characteristics of different blood components, namely, HbO_2
and Hb and also referred to as the coefficient of
15 extinction, differ depending upon which wavelength of light
(e.g., infrared or visible portions of the spectrum) is
being used.

Thus, previously available noninvasive oximetric systems
impinge at least both visible and infrared light upon a
20 body part, such as a finger, and then estimate the SO_2 level
using the relative proportions of visible and infrared
light which was transmitted or reflected. Undesirably,
such systems inherently include some inaccuracy, which
increases to a substantial error for low (50-70%) SO_2
25 levels, due to, among other things, the inclusion of
capillary blood as well as arterial blood in the reading.

In an effort to improve the accuracy of the SO_2 values
obtained using only two wavelengths of light, rather than
the bulky and expensive ear oximeter previously available,
30 which impinged light of eight different wavelengths on the
body part, other apparatus have utilized the pulsatile
component of the transmitted or reflected light beam to
distinguish variations in the detected intensity of the
light beam which are due to changes in blood components
35

-5-

1 from other causes. Generally referred to as pulse
oximetry, using the pulsatile signal modulating the light
beams for S_aO_2 , estimate provides a significant improvement
in accuracy over nonpulse oximetry systems yet still does
5 not distinguish between arterial blood oxygen saturation
and capillary blood oxygen saturation.

The previously available systems and methods of
monitoring blood pressure also all have a variety of
disadvantages. The most commonly performed method, the
10 auscultatory sphygmomanometer method (utilizing a pressure
cuff, mercury manometer, and a stethoscope), often provides
reasonable estimates of systolic and diastolic blood
pressure. But the method does not provide any information
concerning the mean blood pressure or the pressure
15 waveform. Moreover, a trained professional must take one
or more minutes to carry out the method and even then may
be unsuccessful.

Arterial catheterization provides very accurate blood
pressure measurements and waveforms in critical care
20 situations. The extreme invasiveness and the risks of
catheterization, including infection, thrombus formation,
hemorrhage, and cerebral embolization precludes the method
from being routinely used on patients.

In an attempt to provide noninvasive blood pressure
25 monitoring devices, several methods have been suggested in
the past. Devices incorporating a constantly inflated
finger cuff which tracks the pressure changes within the
finger disadvantageously may cause pain to the patient,
interference with the pressure measurement, and/or tissue
30 damage.

In an effort to avoid the disadvantages of using a
constantly inflated pressure cuff, various devices
utilizing photoplethysmography have been introduced. While
such devices utilize a light beam directed at the finger,
35

-6-

1 or other body part, to sense changes in blood vessel volume
in order to determine changes in pressure and thus avoid
the use of a constantly inflated pressure cuff, such
devices still suffer from inaccurate readings, particularly
5 when determining the diastolic pressure, and such devices
still cannot provide an accurate representation of the
arterial pressure waveform.

In view of the disadvantages and drawbacks of the
previously available apparatus and methods, it would be an
10 advance in the art to provide a system and method for
noninvasively measuring arterial blood oxygen saturation
levels while minimizing the effect of capillary oxygen
saturation on the measurement. It would be another advance
to provide a system for measuring both arterial oxygen
15 saturation levels and blood pressure using no more hardware
than necessary to measure oxygen saturation. It would also
be an advance in the art to provide a system and method for
noninvasively measuring blood oxygen saturation levels and
blood pressure which minimizes contact with, and the
20 pressure applied to, the body of the patient. It would be
a further advance in the art to provide a system for
noninvasive blood oximetry or blood pressure monitoring
which may be applied to any one of several parts of the
patient's body.

25 It would also be an advance in the art to provide both
a method and system for blood oximetry and blood pressure
monitoring which may be implemented using little
specialized hardware. It would be yet another advance in
the art to provide a noninvasive blood pressure monitoring
30 system and method which can provide systolic, diastolic,
and mean arterial pressure measurements as well as an
accurate representation of the pressure waveform. Still
another advance in the art would be to provide a
noninvasive system and method for measuring arterial blood
35

-7-

1 oxygen saturation levels which enhances the arterial
contribution and reduces the influence of the capillary
contribution to the oxygen saturation measurement.

5 OBJECTS AND BRIEF SUMMARY OF THE INVENTION

In view of the prior state of the art, it is a primary
object of the present invention to provide a noninvasive
system and method to determine arterial blood oxygen
saturation levels while minimizing the interference of the
10 capillary blood oxygen saturation levels with the
determination of arterial blood oxygen saturation levels.

Another object of the present invention is to implement
a noninvasive system and method for carrying out arterial
blood oximetry which is more accurate than previously
15 available apparatus and methods and which is also capable
of being used on more than one body part of the patient.

It is another object of the present invention to provide
a system and method which allows both blood pressure
monitoring and blood oximetry to be concurrently carried
20 out by the same apparatus. Still another object of the
present invention is to provide a system and method for
noninvasive blood oximetry which can be operated in both a
transmission and reflection mode and can be backed on any
one of a plurality of body parts.

25 It is a still further object of the present invention
to provide a noninvasive blood oximetry and blood pressure
monitoring system and method which does not require that
pressure be applied to the patient's body during the
monitoring interval and that occlusive pressure is applied
30 for only brief durations during calibration intervals.

Yet another object of the present invention is to
provide a noninvasive system and method for both blood
oximetry and accurately determining a patient's systolic,

35

1 diastolic, and mean arterial blood pressure and displaying
the patient's blood pressure waveform.

Additional objects and advantages will be apparent from
the description which follows, or may be learned by the
5 practice of the invention.

Consistent with the foregoing objects, the present
invention provides a noninvasive system and method for
enhanced monitoring of arterial oxygen saturation (S_aO_2)
which may be used alone or in combination with a method for
10 continuously and noninvasively monitoring blood pressure.
When used, the monitoring of blood pressure provides
determinations of systolic pressure, diastolic pressure,
mean arterial pressure, and perhaps most significantly,
producing an accurate arterial pressure waveform. Most
15 advantageously, the present invention allows the same
hardware to be used for both monitoring of arterial oxygen
saturation and monitoring of arterial blood pressure.

The apparatus of the presently preferred embodiment of
the present invention includes a light means comprising two
20 or more light emitting devices which are positioned to
direct at least two light beams into a body part of the
patient. The two light beams are comprised of two
different wavelengths, preferably a reference light beam,
which is absorbed substantially equally by both
25 oxyhemoglobin and reduced hemoglobin, preferably having a
wavelength in the infrared portion of the spectrum and a
measurement light beam, which is absorbed unequally by
oxyhemoglobin and reduced hemoglobin, preferably having a
wavelength in the visible red portion of the spectrum.
30 Other portions of the spectrum may also be used within the
scope of the claimed invention.

Also provided is a detection means, transducer means,
or a photodetector which detects the amount of the light
beams which are absorbed by the blood. The detection means
35

1 and equivalent devices may be positioned to detect either
the light transmitted through, or reflected by, the body
part.

5 Importantly, the visible red light beam which will be
transmitted or reflected will vary according to the ratio
of oxyhemoglobin (HbO_2), to reduced hemoglobin (Hb) in the
blood. Oxyhemoglobin is the component of blood responsible
for carrying almost all of the oxygen to the body tissues.
10 In contrast, the intensity of the detected infrared light
beam will not vary significantly with the ratio of HbO_2 to
Hb. This is due to the fact that the amount of infrared
light absorbed by the body part is affected relatively
little by the changing proportions of HbO_2 and Hb.

15 In accordance with the present invention, an enhancement
means is provided to increase the arterial contribution of
the pulsatile component of the light beams which are
detected by the phototransducer means. The enhancement
means comprises a pressure means for imposing an increased
pressure on the body part.

20 With each heartbeat the volume of the arteries varies
slightly which modulates the intensity of the detected
light beams. The pulsatile component may also be referred
to as the "AC component" of the light beam "signal." The
pulsatile component is impressed upon a relatively steady
25 light beam "signal" referred to as the "DC" "signal." The
importance of the pulsatile component is known to those
skilled in the art and will be further explained later in
this disclosure.

30 The enhancement means operates by applying an increased
enhancement pressure onto the body part into which the
light beams are directed. By applying an enhancement
pressure to the body part, the enhancement pressure being
approximately equal to the mean arterial pressure of the
major artery or arteries located in the body part, the

1 arterial pulsatile component of the light beam detected by
the phototransducer means will be maximized due to
unloading of the transluminal pressure which results in
maximizing arterial compliance. Generally, the increase in
5 the pulsatile component will be about an order of magnitude
greater than the pulsatile component of the detected light
beams without application of the enhancement pressure.

Importantly, application of the enhancement pressure
decreases the relative contribution of the capillary blood
10 oxygen saturation (S_{cO_2}) to the intensity of the detected
light beams. Thus, the increased enhancement pressure both
increases the modulation of the light beam due to the
increase in amplitude of the arterial pulses and by
reducing the amount of capillary blood in the body part.

15 The imposition of the enhancement pressure on the body
part may be considered a "physiological calibration."
Having carried out such a "physiological calibration" by
enhancing the contribution of the pulsatile arterial oxygen
saturation level to the light detected by the
20 phototransducer means, a processor means, for example a
microprocessor or other computing device, may derive a
calibration factor representing the contribution of the
capillary oxygen saturation to the total light detected by
the phototransducer means.

25 The processor means, or microprocessor, controls the
operation of the system to carry out the method of the
present invention to completion and thus continually
updates and displays the arterial oxygen saturation level
of the patient on a display means such as a video monitor.
30 The enhancement pressure may be imposed by a device such as
an inflatable pressure cuff, accompanied by a controllable
pressure pump, adapted for placement on a finger, forehead,
or some other body part.

-11-

1 The enhancement pressure is only applied during a first
interval of the calibration period. During a second
interval of the calibration period, the enhancement
pressure is released and a calibration factor is obtained
5 which reflects the ratio of S_aO_2 to S_cO_2 . After the
calibration period is completed, the monitoring period is
begun and the calibration information is used to determine
the proportion of the pulsatile signal detected by the
phototransducer means which is caused by the arterial
10 oxygen saturation level rather than the capillary oxygen
saturation level.

 The present invention also includes utilizing the above
described hardware for continual blood pressure monitoring
and waveform display. The pressure monitoring function is
15 carried out by determining the mean arterial pressure and
the systolic blood pressure using the oscillometric method.
In the oscillometric method the mean arterial pressure is
determined by adjusting the inflation of a pressure cuff
placed around a body part until the pulsatile signal is
20 maximized. once the amplitude of the pulsatile signal is
maximized, the pressure within the cuff is approximately
equal to the mean arterial pressure.

 The oscillometric method determines the systolic
pressure by increasing the pressure applied to a body part
25 to above the systolic pressure, i.e., completely occluding
the artery so that no pulsatile signal is present, and then
gradually reducing the pressure within the cuff until a
pulsatile signal appears, providing a data point which can
be used to calculate the patient's systolic pressure using
30 a procedure described herein.

 Advantageously, the present invention also provides for
calculation of a complete pressure waveform and diastolic
pressure. With the mean arterial pressure and the systolic
pressure being known, the present invention allows the
35

-12-

1 change in volume of the artery, which is proportional to
the pressure within the artery, to be detected by the
phototransducer means as a modulation of the intensity of
the measurement (red) light beam directed into the body
5 part.

The pressure-volume relationship of an artery is not
linear or the same from patient to patient or from hour to
hour. The pressure-volume relationship of the patient's
artery may be described and predicted using a model known
10 as the "Hardy model compliance curve." The information
needed to determine the pressure-volume relationship,
including the systolic pressure and the mean arterial
pressure, are obtained using the oscillometric method
during the calibration period when the pressure cuff is
15 inflated in the below-described manner.

During the monitoring period, the pressure within the
cuff is released and the volume change in the artery is
detected by the phototransducer means. The present
invention then uses a recursive procedure wherein an
20 estimated diastolic pressure and the Hardy model compliance
curve is used to derive a calculated mean arterial
pressure. If the difference between the calculated mean
arterial pressure and the measured mean arterial pressure
is within a predetermined standard, then the estimated
25 diastolic pressure is displayed on the display means as the
patient's diastolic pressure. If the calculated mean
arterial pressure and the measured mean arterial pressure
do not agree within predetermined limits, a new estimated
diastolic pressure is chosen and the calculations repeated
30 until the estimated diastolic pressure produces a
calculated mean arterial pressure substantially the same as
the measured mean arterial pressure.

As the diastolic blood pressure is being calculated,
three parameters required to determine the pressure-volume
35

-13-

1 relationship in the artery using the Hardy model are being
calculated. The three parameters include:

5 k = compliance index for the arterial blood vessels
of the patient;

V_m = maximum volume of the arterial blood vessels in
the patient's body part; and

V_0 = volume of the arterial blood vessels in the
patient's body part at zero pressure

10 Importantly, using the described method, the value of
any point on a blood pressure waveform between the systolic
and diastolic pressures may be calculated. Thus, a
continuous and complete blood pressure waveform may be
generated using the method. The ability to calculate a
15 complete and accurate representation of the patient's
arterial blood pressure waveform is a great advance over
previously available systems using photoplethysmography.

Further information concerning the pressure monitoring
function of the present invention will be provided later in
20 this disclosure as well as being provided in United States
Patent Application Serial No. 07/068,107 entitled
"Noncontactive Arterial Blood Pressure Monitor and
Measuring Method" filed on June 29, 1987, which is
incorporated herein by reference.

25 As will be more fully appreciated during a description
of the remainder of this disclosure, the blood oximetry
functions of the present invention may be carried out alone
or a system can be designed to carry out the oximetry
function as well as the blood pressure monitoring function
30 without requiring any hardware in addition to that used to
carry out the oximetry function of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a perspective view of the presently
preferred embodiment of the present invention which is

35

-14-

1 configured to provide both blood pressure monitoring and
arterial oxygen saturation monitoring functions.

Figure 2 is a block diagram of the system of the
presently preferred embodiment of the present invention.

5 Figure 2A is a cross sectional view of another preferred
embodiment of the pressure cuff represented in Figure 2.

Figures 3A and 3B are flow charts representing the steps
of one presently preferred method of the present invention
for determining arterial blood oxygen saturation levels.

10 Figure 4 is a waveform diagram showing the application
and release of pressure on the patient's body by the
pressure cuff of the described embodiment and its effect on
the detected light beams.

Figures 5A and 5B are flow charts representing the steps
15 of another presently preferred method of the present
invention for determining arterial blood oxygen saturation
levels.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Reference will now be made to the drawings to describe
20 the presently preferred embodiment of the present
invention. While the embodiment described herein performs
both blood oxygen saturation and blood pressure monitoring
functions, a system carrying out only the blood oxygen
saturation monitoring function may be constructed if
25 desired. Furthermore, the described embodiment is only
illustrative of one of the many possible embodiments for
carrying out the present invention.

Continuous transportation of oxygen to the cells of the
body is essential to the well-being of the patient. Nearly
30 all of the oxygen transported from the lungs to the rest of
the body is carried by hemoglobin stored in the
erythrocytes or red blood cells. As hemoglobin releases
carbon dioxide and combines with oxygen its color changes
from cyan to a bright red. Arterial oxygen saturation

35

-15-

1 (S_aO₂) is expressed as a percentage of the maximum oxygen
which the arterial blood can carry. An oxygen saturation
level of about 95%-98% is considered normal in most
patients.

5 Significantly, both hemoglobin and oxyhemoglobin have
approximately the same absorption coefficient for light in
the infrared portion of the spectrum. However, the
absorption coefficients of the two compounds is very
different for red light in the visible portion of the
10 spectrum. The difference in absorption coefficients allow
S_aO₂ to be measured noninvasively using two light beams of
two appropriate and differing wavelengths. It should be
appreciated that the phrase "light beam" as used herein is
intended to include any electromagnetic radiation having an
15 appropriate wavelength which is directed toward, or
impinged upon, the patient's body regardless of whether the
light beam is collimated or uncollimated, coherent or
incoherent.

20 Figure 1 provides a perspective view of the major
components of the described embodiment including a micro
computer 10, a visual display 12, a pump 28 (incorporating
a pump driver), a finger cuff 34 (incorporating a pressure
cuff, light emitting diodes, and a phototransducer), as
well as cables 26 and 30, and tubing 32 interconnecting the
25 components. It will be appreciated that components which
are equivalent to many of the functional blocks represented
in Figure 2 are contained within the structures illustrated
in Figure 1 and thus are not separately represented in
Figure 1.

30 Shown in Figure 1 is a patient's finger 36 and the
presently preferred embodiment of the present invention
being used to determine the patient's S_aO₂ level at the
numerical display represented generally at 12. The
patient's blood pressure is also being monitored with the
35

-16-

1 systolic, mean, and diastolic blood pressure values being
provided at numerical displays represented generally at 20,
18, and 16, respectively. The patient's blood pressure
5 waveform is also being shown on the visual display
indicated at 22.

The illustrated embodiment, as well as other embodiments
of the present invention, have application in many
circumstances. Such circumstances may include patients
undergoing anesthesia during surgery, critical and
10 intensive care units, exercise and sleep studies, as well
as other applications.

In Figure 1 the sensing elements of the embodiment,
including the pressure cuff 34 which surrounds the light
emitting diodes, the photodetector, and the pressure
15 transducer, are located between the first and second
knuckle of the patient's index finger. While this position
is illustrated for purposes of describing the presently
preferred embodiment, other positions on the body may be
used in specific circumstances as will be discussed later.
20 Also, the specific arrangement of the sensing elements in
relation to the body part will be described as appropriate
in the description of the preferred embodiment.

Figure 2 illustrates the major functional blocks of the
embodiment illustrated in Figure 1 and described herein.
25 It is to be understood that the hardware represented by the
functional blocks illustrated in Figure 2 may be
implemented in many different ways.

In the presently preferred embodiment, the microcomputer
may be a general purpose microcomputer 40 such as an IBM
30 Personal Computer or an equivalent device. Alternatively,
it may be desirable to utilize a more powerful
microcomputer or to devise a microprocessor-based apparatus
specifically designed to carry out the data processing
functions incidental to this invention. When choosing a

35

-17-

1 microcomputer, if both the blood oximetry and the blood
pressure monitoring (including waveform display) are to be
carried out and displayed in real time, the microcomputer
40 or other processor means must carry out a large number
5 of computations very quickly.

Importantly, the hardware which embodies the processor
means of the present invention must function to perform the
operations essential to the invention and any device
capable of performing the necessary operations should be
10 considered an equivalent of the processor means. As will
be appreciated, advances in the art of modern electronic
devices may allow the processor means to carry out
internally many of the functions carried out by hardware
illustrated in Figure 2 as being independent of the
15 processor means. The practical considerations of cost and
performance of the system will generally determine the
delegation of functions between the processor means and the
remaining dedicated hardware.

As can be seen in Figure 2, in the presently preferred
20 embodiment microcomputer 40 is interconnected with the
remaining apparatus hardware by way of I/O ports 44 and a
plurality of analog to digital converters 46. Also, a
visual display 42 is connected to the microcomputer 40.

Visual display 40 performs the function of a display
25 means. As intended herein, the display means may be any
device which enables the operating personnel to observe the
values and waveforms calculated by the microcomputer.
Thus, the display means may be a device such as a cathode
ray tube, an LCD display, a chart recorder, or any other
30 device performing a similar function.

The method of the present invention is carried out under
the control of a program resident in the microcomputer.
Those skilled in the art, using the information given
herein, will readily be able to assemble the necessary
35

-18-

1 hardware, either by purchasing it off-the-shelf or by
fabricating it and properly program the microcomputer in
either a low level or a high level programming language.
While it is desirable to utilize clock rates that are as
5 high as possible and as many bits as possible in the A/D
converters 46, the application of the embodiment and
economic considerations will allow one skilled in the art
to choose appropriate hardware for interfacing the
microcomputer with the remainder of the embodiment. Also,
10 it should be understood that for reasons of simplifying the
diagrams, power supply connections, as well as other
necessary structures, are not explicitly shown in the
figures, but are provided in actuality using conventional
techniques and apparatus.

15 As represented in Figure 2, an LED current driver 48 is
provided. The LED current driver 48 controls the amount of
current directed to the infrared LED and the red LED.
Since LEDs are current controlled devices, the amount of
current passed through the devices determines, within
20 device limits, the intensity of the light beam emitted
thereby.

Schematically shown in Figure 2 is a side view of a
patient's finger 36 with the pressure cuff 34 shown in
cross section, also referred to as the enhancement means,
25 which surrounds the finger. Disposed on the interior of
the pressure cuff are the infrared LED 56, the red LED 54,
and a photodiode 64.

Both the infrared LED 56 and the red LED 54 may be
devices which are commonly available in the semiconductor
30 industry. They provide high power outputs and relatively
stable operation at a reasonable cost per device. The red
LED 54 preferably emits a light beam having a wavelength of
660 nanometers and the infrared LED 56 preferably emits a
light beam having a wavelength of 930 nanometers.

35

-19-

1 Light emitting devices other than those mentioned above
could be used and are intended to be within the scope of
the inventive concepts claimed herein. The light emitting
5 devices may be placed outside of the pressure cuff 34 with
a fiber optic pathway provided to the interior of the
pressure cuff. Furthermore, other wavelengths of light may
be used as suitable devices for generating such wavelengths
become available.

10 As used herein, the phrase light means is intended to
include the above-mentioned LEDs as well as any devices
which perform functions equivalent to those performed by
the LEDs. As will be appreciated by considering the
foregoing discussion, any source or sources of light
15 capable of emitting light having two differing and
appropriate wavelengths may function as the light means.
Thus, for example, unitary light emitting devices capable
of emitting two or more wavelengths of light, or devices
emitting wavelengths of light other than those specified
above, are within the intended scope of the phrase
20 structure defined by light means.

The photodiode 64 disposed within the pressure cuff 34
is preferably one having a spectral response which is
substantially equal at the wavelengths emitted by the
infrared LED 56 and the red LED 54 and which, like the
25 LEDs, is capable of stable operation over a long period of
time. It may be desirable to include a temperature sensing
device (not shown) adjacent the LEDs and the photodiode to
provide the microcomputer 40 data on the temperature
dependent variations in the operations of LEDs 54 and 56
30 and the photodiode 64. It is preferable that the LEDs and
the photodiode be readily replaceable so that any drift
which occurs in the operating parameters of the devices
(possibly due to the effects of aging) may be remedied by
replacing old components with new ones.

35

-20-

1 The functions carried out by photodiode 64 may be best
labeled by the phrases detection means, light detection
means, and transducer means. Importantly, any device which
performs the function of detecting the amount of light
5 transmitted through, or reflected from, a body part and
creating an electrical signal of some kind which contains
information on the intensity of the light striking the
device may function as the detection means, light detection
means, or transducer means.

10 As will be appreciated by those skilled in the art,
phototransducers such as phototransistors and many other
devices now available, or available in the future, have
application within the scope of the present invention.
Methods for determining arterial blood oxygen levels using
15 either light beams passed through, or reflected from, a
body part will be described later in this disclosure.

It is presently preferred that the LEDs 54 and 56 be
positioned about the finger so that the light beams pass
through the digital arteries on each side of the phalanx
20 bone. Thus, the arterial blood's contribution to the
modulation of the light beams is maximized rather than the
light beams being absorbed by tissue and bone. Also,
rather than having a single LED located on each side of the
phalanx bone, a pair of LEDs, each pair including a red LED
25 and an infrared LED, may be positioned immediately adjacent
each other. Each pair of LEDs is positioned on the
interior of the pressure cuff so that the respective light
beams pass through one of the arteries located on each side
of the phalanx bone of the finger. This provides that both
30 an infrared and a red light beam will be equally modulated
by the same artery.

Also represented in Figure 2 is a pressure transducer
58. The pressure transducer 58 is used when determining the
patient's blood pressure but is not necessary to the blood

35

-21-

1 oximetry function of the present invention. Pressure
transducer 58 acts as a pressure detection means or a
pressure transducer means and functions to generate an
electrical signal which is proportional to the pressure
5 being imposed upon the body part by the pressure cuff.
Thus, any device performing the same, or an equivalent
function, should be considered a pressure detection means
or pressure transducer means.

10 Alternatively, rather than locating the sensing elements
on the patient's finger, the sensing elements may be
located on body parts such as on a toe, ear, the web of the
hand, or over the temporal artery on the patient's
forehead. of course, each of these locations will require
15 a different arrangement for the pressure cuff or other
structure for imposing the enhancement pressure.

In particular, locating the sensing structures over the
temporal artery on the forehead requires that the LEDs and
photodiode be positioned so that the photodiode senses the
light beams which are reflected from, rather than
20 transmitted through, the body part. Furthermore, a
structure other than a pressure cuff must be used to apply
pressure to the temporal artery and to hold the pressure
imposing device in place. Still, the temporal artery may
be the most preferred location for the sensing structures
25 in many cases due to the fact that perfusion at the
temporal artery is affected less by vascular disease and
drugs than the arteries found in the extremities. Thus,
use of the temporal artery may provide more accurate S_aO_2
determinations than a location on a patient's extremities,
30 in some cases.

As shown in Figure 2, an LED multiplexer 52, driven by
a clock 50, alternately connects the current driver 48 to
either the infrared LED 56 or the red LED 54. The
operation of the clock 50 and the LED multiplexer 52
35

-22-

1 ensures that only one of either the red LED 54 or the
infrared LED 56 will operate at one time. The output of
clock 50 is also input to channel multiplexer 74 to provide
synchronized operation.

5 The pressure cuff 34 should be opaque so that the
photodiode 64 is shielded from any stray ambient light.
The pressure cuff 34 is inflated and deflated by a pump 68
which operates under the control of the pump driver which
is in turn controlled by the microcomputer 40.

10 As suggested earlier, if the embodiment is to be used
only for determinations of S_aO_2 , the pump 68 need only be
capable of inflating the pressure cuff 34 to a pressure
equal to the mean arterial pressure. If the embodiment is
to be used to also determine blood pressure, the pump 68
15 should be capable of inflating the pressure cuff 34 to a
pressure well above the patient's systolic pressure so that
the arteries may be completely occluded and the systolic
pressure determined as explained earlier.

The pressure cuff 34, pump 68, and pump driver 70
20 comprise the enhancement means or pressure means of the
present invention. As will be appreciated from the
previous discussion concerning the application of mean
arterial pressure on an artery and its effect on the
arterial pulsatile signal, any structure which functions to
25 partially or fully occlude a patient's artery should be
considered the equivalent of the enhancement means or
pressure means. The body part which is used as a sensing
location will often dictate the best devices and structures
used as the enhancement or pressure means.

30 As illustrated in Figure 2, a preamplifier 66 receives
the output of the photodiode 64. The preamplifier 66
boosts the photodiode output to a level usable by the
automatic gain control (AGC) 72. The automatic gain
control 72 functions to limit the dynamic range of the

35

-23-

1 voltage signal output from the preamplifier 66 to that which is appropriate for the circuits which follow.

2 The gain-controlled output from the AGC 72 is applied
3 to a channel multiplexer 74 which is also driven by the
4 clock 50. Thus, when the LED multiplexer 52 causes the red
5 LED 54 to operate, the output of the AGC 72 is directed to
6 Channel 1 (red) as represented at 76 in Figure 2.
7 Conversely, when the LED multiplexer 52 causes the infrared
8 LED 56 to operate, the output of the AGC 72 is directed to
9 Channel 2 (infrared) as represented at 78 in Figure 2.
10

11 Each channel 76 and 78 includes a low pass filter 80
12 and 82 to reduce high frequency (e.g., ≥ 40 Hz) noise. The
13 signal output from each of the low pass filters 80 and 82
14 is applied to pulsatile signal amplifiers 84 and 86,
15 respectively, which include high-pass filters to prevent
16 passage of direct current and very low frequencies (e.g.,
17 ≥ 1 Hz). Thus, the pulsatile signal amplifiers 84 and 86
18 can be thought of as AC amplifiers. The output of the
19 pulsatile signal amplifiers provide Δ_{IR} signal and, ΔV_R
20 signal to the microprocessor by way of the A/D converters
21 46. The Δ_{IR} and ΔV_R signals reflect only the AC, i.e.,
22 pulsatile, component of the light beams passed through the
23 patient's body part.

24 The total signal amplifiers 88 and 90, one provided for
25 each channel, are not frequency limited and thus pass to
26 their outputs an amplified waveform containing both the DC
27 and AC components of the V_{IR} and V_R signals which were
28 output from the low pass filters 80 and 82, respectively.

29 With the hardware assembled as illustrated in Figure 2,
30 data concerning all of the variables which must be
31 considered to determine both the patient's S_aO_2 level and
32 blood pressure is presented to the microcomputer for
33 processing according to the method of the present
34 invention. In summary, the microcomputer 40 controls the
35

1 intensity of the LEDs 54 and 56, the inflation of the
pressure cuff 34, and the gain of the output from the
photodiode 64. The microcomputer receives as input data,
the ΔV_{IR} and ΔV_R signals (pulsatile component of the
5 signals) and the V_{IR} and V_R signals (the total signals
including both the AC and DC components).

The presently preferred method of the present invention
is carried out by the system illustrated in Figure 2 and
comprises those steps illustrated in the flow chart of
10 Figure 3. In order to explain one method of the preferred
embodiment, Figures 3 and 3B will be used with reference to
the waveform diagrams of Figure 4 as well as the block
diagram of Figure 2.

The flow chart of Figures 3 and 3B represents just one
15 of the many embodiments which may be used to carry out the
method defined in the claims. Particularly, with the
widespread availability of powerful microprocessors, the
present invention requires little specialized hardware and
the data acquisition and manipulations steps described
20 herein may be varied and yet still be within the scope of
the invention as defined in the claims. In order to
clarify the following description, the blood oximetry
function of the present invention will first be explained
and then the combination of the blood oximetry function and
25 the blood pressure monitoring function will be explained.

It should be noted that the flow chart of Figure 3 is
divided into three principal periods: the initialization
period, the calibration period, and the monitoring period.
Furthermore, the calibration period is divided into an
30 enhancement pressure-on interval when the enhancement
pressure is applied to the patient's body part and an
enhancement pressure-off interval when the enhancement
pressure is not applied.

-25-

1 Briefly, the steps carried out during the initialization
period include those pertaining to determining certain set
up parameters, and implementing any software routines which
must be running while data is being acquired. The steps
5 carried out during the calibration period include imposing
an increased enhancement pressure on the body part,
acquiring data, determining the S_aO_2 with the enhancement
pressure on, and then with the enhancement pressure off,
continuing to acquire data which can be used to determine
10 a "physiological calibration factor" which is used during
the monitoring period. During the monitoring period no
pressure is applied to the body part and further data is
obtained to determine the patient's SO_2 level. The data
previously acquired and the resulting calculated values are
15 used according to the method described herein to determine
the S_aO_2 level during the monitoring period.

As shown in the flow chart of Figures 3 and 3B, the
method of the present invention begins during the
initialization period with the initialization of the
20 hardware and software of the system as represented at step
100. Those skilled in the application of microprocessors
to medical monitoring situations will understand the
various software routines which should be run after power
is applied, but before data is acquired. For example, as
25 represented at step 102, it is very desirable to implement
a conventional noise discrimination routine.

In the present case, such a noise discrimination routine
may be one known to those skilled in the art which includes
an algorithm to distinguish information associated with
30 each pulse and heart beat from noise, which in the present
system, may be due to ambient light temporarily striking
the photodiode or artifacts in the signals caused by motion
of the patient. During such a noise discrimination routine,
the patient's heart rate will be determined and may be
35

-26-

1 displayed for the information of the attending medical professional.

As mentioned earlier, the calibration period includes an "enhancement pressure-on interval" and an "enhanced
5 pressure-off interval" which is followed by a monitoring period. The length of each of these periods (T_{EP} , T_{NP} , and T_{MON} , respectively) are determined at step 104 according to the criteria discussed below. While not represented in the flow chart of Figure 3A, in some embodiments it may be
10 desirable to include a software routine which will vary T_{EP} , T_{NP} , and T_{MON} according to the physiological condition of the patient.

It is known that application of pressure on a body part which causes even partial occlusion of blood vessels and
15 capillaries to some extent has an effect on perfusion in the body part. Significantly, if pressure is applied to a body part long enough, the actual blood pressure found in the blood vessels will begin to change due to changes in the blood vessels involved. Furthermore, determinations of
20 S_aO_2 become more difficult and less reliable the longer the pressure is applied. Moreover, from the view point of the unanesthetized patient, application of pressure on a body part will result in pain.

Thus, it is important that the time that the enhancement
25 pressure is imposed be limited to avoid pain in the unanesthetized patient and in all patients to avoid altering the patient's blood pressure and S_aO_2 . In general cases, T_{EP} will be less than or equal to about 0.2 to about 0.5 of the sum of T_{NP} and T_{MON} resulting in a pressure
30 imposed duty cycle of less than about 20% to about 50%.

With the above considerations in mind, it is necessary to determine how long the calibration period ($T_{EP} + T_{NP}$) should be in relation to the length of the monitoring period which will also determine how often the steps of the
35

-27-

1 calibration period are carried out. Importantly, the
calibration period must be long enough to allow accurate
data to be collected. Additionally, since physiological
5 parameters change over time, and may change rapidly due to
stress, injury to the patient, drugs, or other treatment
administered to the patient, the steps of the calibration
period must be carried out regularly.

For example, if a patient's condition is rapidly
changing and the patient is unconscious, it may be
10 desirable to carry out the steps of the calibration period
for as long as the steps of the monitoring period are
carried out in order to obtain the most accurate and
constantly updated information to the attending physician.
Moreover, in many patients suffering from vascular disease,
15 poor perfusion may cause reliable S_aO_2 determinations to be
available only when the enhancement pressure is imposed
upon the body part.

Once the initialization period steps have been
completed, the enhancement pressure is applied to the body
20 part as represented at step 106. As explained earlier, the
enhancement pressure may be applied to one of several body
parts containing a significant artery. As explained
earlier, the imposition of the enhancement pressure
accomplishes two primary results: Increasing the amplitude
25 of the AC (or pulsatile) component of the arterial pulse
component of the transmitted (or reflected in the case of
the method represented in Figures 5A and 5B) light beams;
and Decreasing the absorption of the light beams by blood
in the capillaries increasing the amplitude of the AC (or
30 pulsatile) component of the arterial pulse of the artery.
Both of these results allows more accurate noninvasive S_aO_2
determinations than previously possible. Such accurate S_aO_2
determinations are even possible under conditions of
relatively low perfusion. As will now be recognized, the
35

-28-

1 enhancement pressure is so named because the contribution of the arterial blood to the SO_2 determination is enhanced.

The result of increasing the amplitude of the pulse of the artery is brought about by the well known effect that
5 the amplitude of the blood pressure pulses is maximized as the pressure imposed upon the artery equals the mean arterial pressure. The increase in artery pulses, i.e., the pulsatile signal detected by the system, allows more accurate S_aO_2 determinations even under conditions of low
10 perfusion. Because the difference between S_aO_2 and S_cO_2 may vary dramatically from patient to patient and from hour to hour, the "physiological calibration" carried out by the present invention is essential to improving the accuracy of S_aO_2 determinations.

15 In practice, it is not necessary for the blood oximetry system to hold the enhancement pressure at exactly the mean arterial pressure for the entire enhancement pressure-on interval. As shown in Figure 4 at waveform A, when the enhancement pressure is increased to, for example, 100 mmHg
20 (assuming the mean arterial pressure is 100 mmHg) the pulsatile signals ΔV_R and ΔV_{IR} (waveforms B and D, respectively) increase by about an order of magnitude. Thus, the enhancement pressure need only be about equal to the mean arterial pressure to cause the desired increase in
25 the pulsatile signals (ΔV_R and ΔV_{IR}).

Rather than holding the enhancement pressure exactly on the mean arterial pressure, it may be useful to slowly ramp the enhancement pressure (e.g., 5 mmHg/sec), particularly when a ramping pressure must be imposed to accurately
30 determine the mean arterial pressure for use in blood pressure.

As shown at step 108 in Figure 3A, after the enhancement pressure has been imposed, it is generally necessary to wait at least two heart beats so that the physiological
35

-29-

1 parameters can stabilize after changing the pressure
imposed upon the body part. Once the physiological
parameters have stabilized, it is necessary to determine
5 values for the following variables as shown at 110 in
Figure 3:

$\Delta V_{R_{EP}}$ = the pulsatile signal output from the
photodiode when the red LED is operating
during the enhancement pressure-on interval

10 $\Delta V_{IR_{EP}}$ = the pulsatile signal output from the
photodiode when the infrared LED is
operating during the enhancement pressure-
on interval

$\bar{V}_{R_{EP}}$ = the average of the total signal output from
the photodiode when the red LED is operating
15 during the enhancement pressure-on interval

$\bar{V}_{IR_{EP}}$ = the average of the total signal output from
the photodiode when the infrared LED is
operating during the enhancement pressure-
on interval

20 The $\Delta V_{R_{EP}}$ and $\Delta V_{IR_{EP}}$ are input to the microcomputer by
way of the appropriate channel amplifiers and analog to
digital converters. The $\bar{V}_{R_{EP}}$ and $\bar{V}_{IR_{EP}}$ values are calculated
by the microcomputer by the data received from the total
signal amplifiers 88 and 90 and the analog to digital
converters 46. Figure 4 provides representative waveforms
25 suggesting relative values of the listed variables.

In practice, the waveforms are not continuous but are
time division multiplexed with Channel 1 (the red channel)
and Channel 2 (the infrared channel) each having a voltage
from the photodiode gated to the channel amplifiers an
30 equal amount of time. However, the gating of the output of
the photodiode is not represented in waveforms B, C, D, and
E in order to increase the clarity of the waveforms.
Moreover, the operation of the clock represented in Figure
2 desirably may be synchronized with the operation of the
35

1 analog-to-digital converters and also should be fast enough
that a very accurate representation of the waveforms may be
preserved.

5 Each of these waveforms is represented in Figure 4. As
shown at waveforms B and D during T_{EP} , the ΔV_R and ΔV_{IR}
waveforms include only the C or pulsatile component of the
photodiode signal as processed by, and output from, the
pulsatile signal amplifiers of each channel. The V_R and the
10 V_{IR} represented by waveforms C and E, respectively, of
Figure 4, are an average, or more specifically a mean, of
the total signal output from the photodiode.

It will be appreciated that in the described embodiment
the signal output from photodiode 64 will be expressed and
processed in terms of a voltage, hence the label "V."

15 In particular, the $\bar{V}_{R_{EP}}$ and the $\bar{V}_{IR_{EP}}$ signals are not
directly measured but are determined mathematically by the
microcomputer hardware and software from the signal output
from the total signal amplifiers 88 and 90 of each channel
and digitized by the analog-to-digital converters 46. It
20 will be appreciated that much of the signal processing
hardware may be eliminated by assigning more of the signal
processing to the microcomputer without departing from the
spirit and essential characteristics of the system and
method of the present invention. Nevertheless, in order to
25 arrive at an appropriate balance between speed of
operation, flexibility, accuracy, and cost of the system,
the dedicated hardware, such as the amplifiers 84, 86, 88,
and 90, which is illustrated and described is preferably
included in the system.

30 Next, as represented at step 112, the average (mean) of
multiple determinations of $\Delta V_{R_{EP}}$, $\Delta V_{IR_{EP}}$, $\bar{V}_{R_{EP}}$, and $\bar{V}_{IR_{EP}}$ are
each calculated and stored until the elapsed time of the
enhancement pressure on interval (t_{EP}) is equal to or
greater than the preset enhancement pressure interval T_{EP} ,
35

-31-

1 as represented at step 114. It will be realized that in
 some circumstances it may be desirable to express T_{EP} , and
 the other periods and intervals discussed herein, in terms
 of the number of heartbeats which have occurred rather than
 5 on a set period of time. Still further, it may be useful
 in some cases to include algorithms in the embodied method
 of the present invention which may switch between using
 heartbeats and set time periods for the intervals and which
 may also vary the length, whether time or heartbeats, of
 10 the intervals.

Each average determined from the $\Delta V_{R_{EP}}$, $\Delta V_{IR_{EP}}$, $\bar{V}_{R_{EP}}$,
 and $\bar{V}_{IR_{EP}}$ signals are individually stored in the
 microcomputer's memory.

15 Next, as shown at Step 116, a value for $RLOG_{EP}$ using
 equation (1) is determined using the stored average values:

$$RLOG_{EP} = \frac{\log (1 + \Delta V_{R_{EP}} / \bar{V}_{R_{EP}})}{\log (1 + \Delta V_{IR_{EP}} / \bar{V}_{IR_{EP}})} \quad (1)$$

20

Equation (1) is applied to a data obtained by
 transmitting the light beams through a body part since the
 transmission of light through whole blood only somewhat
 25 follows the LambertBeers law. Equation (1) requires that
 the log of the pertinent values be calculated. This
 equation is familiar to those skilled in the art and may
 be easily carried out by the microcomputer.

However, since transmission of light through whole blood
 30 results in values which deviate significantly from the
 LambertBeers law once a value for $RLOG_{EP}$ is calculated and
 stored, the S_aO_2 corresponding to the $RLOG_{EP}$ value is found
 by reference to a $RLOG_{EP}$ look-up table as indicated at step
 118. The $RLOG_{EP}$ look up table is derived from empirical data

35

-32-

1 gathered during use of the system described herein. For
example, once a red LED, infrared LED, photodiode, and
other hardware items have been configured to provide the
system described herein, the values obtained for $RLOG_{EP}$ may
5 be correlated with the S_aO_2 value obtained using another
 S_aO_2 determination method, for example, an in vitro method.
Alternatively, the subject's S_aO_2 may be altered by altering
the composition of the inspired gases and monitoring the
composition of the expired gases. Once the look-up table
10 has been completed, it can be used in the case of any
number of patients if the performance of the apparatus
hardware is maintained within appropriate parameters
considering the effects of age, temperature, and
variability of mass produced components.

15 The S_aO_2 which was determined from the $RLOG_{EP}$ look-up
table at step 118 is displayed as represented at step 120
in Figure 3 on the display means 42 represented in Figure
2. It should be appreciated that the S_aO_2 value displayed
at step 120 during the enhancement pressure on interval is
20 more accurate and reliable than S_aO_2 values provided by
previously available pulse oximetry systems due to the
enhancement of the arterial pulsatile signal output from
the photodiode and the decrease of the capillary oxygen
saturation contribution to the same signal.

25 Nevertheless, the interval during which the enhancement
pressure is imposed must be limited due to several
considerations including avoiding pain for the patient and
affecting the physiology of the patient so that the
measurements obtained are altered in any significant
30 fashion. Thus, the enhancement pressure is released from
the body part for the remainder of the calibration period
and monitoring period as represented at step 122 as shown
in Figure 3B.

-33-

1 As shown in Figure 4, the enhancement pressure-off
 interval of the calibration period begins when the
 enhancement pressure is released and the pressure on the
 body part returns to the ambient pressure. Again, as
 5 represented at step 124, it is necessary to wait at least
 two heartbeats before measuring any variables.

Continuing to refer to Figure 3B and similarly to the
 steps taken during the enhancement pressure-on interval,
 the enhancement pressure-off interval includes steps to
 10 determine four variables as shown at Step 126.

$\Delta V_{R_{NP}}$ = the pulsatile signal output from the
 photodiode when the red LED is operating
 during the enhancement pressure-off interval

15 $\Delta V_{IR_{NP}}$ = the pulsatile signal output from the
 photodiode when the infrared LED is operating
 during the enhancement pressure-off interval

$\bar{V}_{R_{NP}}$ = the average of the total signal output from
 the photodiode when the red LED is operating
 during the enhancement pressure-off interval

20 $\bar{V}_{IR_{NP}}$ = the average of the total signal output from
 the photodiode when the infrared LED is
 operating during the enhancement pressure-off
 interval

25 Also, similarly to the steps taken during the
 enhancement pressure-on interval, the average of multiple
 determinations of the enhancement pressure-off interval
 variables (step 128) is calculated until the length of the
 enhancement pressure-off interval (t_{NP}) is equal to or
 30 greater than the time previously set for the enhancement
 pressure-off interval (T_{NP}) as represented at step 130 in
 Figure 4.

A value for $RLOG_{NP}$ is then obtained as represented at
 step 132 in accordance with equation (2) shown below:

35

-34-

$$\begin{aligned}
 & \log (1 + \Delta V_{R_{NP}} / \bar{V}_{R_{NP}}) \\
 RLOG_{NP} = & \frac{\log (1 + \Delta V_{R_{NP}} / \bar{V}_{R_{NP}})}{\log (1 + \Delta V_{IR_{NP}} / \bar{V}_{IR_{NP}})} \quad (2)
 \end{aligned}$$

Then, having calculated and stored both $RLOG_{EP}$ and $RLOG_{NP}$, R may be calculated according to equation (3) below:

$$R = (RLOG_{EP} / RLOG_{NP}) \quad (3)$$

Where C is a calibration function given by equation (4) below:

$$C = F(SO_2)_{NP} / F(SO_2)_{EP} \quad F(SO_2)_{EP} \quad (4)$$

where:

$F(SO_2)_{NP}$ = the inverse of the look-up table function for functional oxygen saturation without the enhancement pressure imposed

$F(SO_2)_{EP}$ = the inverse of the look-up table function for functional oxygen saturation with the enhancement pressure imposed

Thus, C in equation (4) represents a calibration factor which must be introduced to maintain accuracy of the system because of the differences, which may be very small, between the look-up tables for $RLOG_{EP}$ and $RLOG_{MON}$. Having calculated R in accordance with equation (3), corrections can be made to subsequent S_aO_2 measurements to account for the effect of S_cO_2 and to reduce or eliminate the contribution of S_cO_2 on the S_aO_2 determination leaving just the S_aO_2 level to be displayed to the physician. Having carried out these steps, the calibration period is completed.

The first step in the monitoring period (t_{MON}) shown at 136 in Figure 3B, requires that the values for the following variables be determined:

-35-

1 ΔV_{R_MON} = the pulsatile signal output from the photodiode when the red LED is operating during the monitoring period

5 ΔV_{IR_MON} = the pulsatile signal output from the
photodiode when the infrared LED is operating
during the monitoring period

$\bar{V}_{R_{MON}}$ = the average of the total signal output from the photodiode when the red LED is operating during the monitoring period

\bar{V}_{IR_MON} = the average of the total signal output from the photodiode when the infrared LED is operating during the monitoring period

15 Next, at step 138, a running average of the four variables is calculated. It may be desirable to allow the physician using the system of the present invention to determine how heavily past values for the four variables will be weighted in subsequent calculations.

20 As will be appreciated, weighing previously obtained determinations of the four variables will result in a displayed S_aO_2 value which is more immune to motion artifacts, noise, and spurious signals but which is less responsive to rapid changes in S_aO_2 levels. Alternatively, 25 if the previously obtained values for the four variables are weighted little or not at all, then the system will be very responsive to rapid changes in S_aO_2 levels but motion artifacts, noise, and supurious signals may cause the display of an occasional inaccurate S_aO_2 value. When such 30 an inaccurate S_aO_2 value is displayed, the physician will need to judge whether the display is an accurate reflection of the patient's condition or is caused by sources other than the patient's S_aO_2 levels.

-36-

1 Next as shown at step 140, values for ΔV_{aR} and ΔV_{aIR} are calculated according to equations (5) and (6), provided below:

$$\Delta V_{aR} = \Delta V_R(1-aR) \quad (5)$$

5

$$\Delta V_{aIR} = \Delta V_{IR}(1-a) \quad (6)$$

where a equals the capillary pulse volume fraction.

10 Next, at step 142, $RLOG_a$ is calculated according to equation (7):

$$RLOG_a = \frac{\log(1 + \Delta V_{aR}/\bar{V}_R)}{\log(1 + \Delta V_{aIR}/\bar{V}_{IR})} \quad (7)$$

15

Having calculated $RLOG_a$, the S_aO_2 level may be determined by obtaining a value from the $RLOG_{a_{MON}}$ look-up table as represented at step 144. The $RLOG_{a_{MON}}$ look-up table is derived empirically in a fashion similar to that described earlier for the $RLOG_{EP}$ look-up table. Significantly, the value obtained from the $RLOG_{a_{MON}}$ look-up table represents the S_aO_2 value since the S_cO_2 contribution has already been "calibrated out" by the steps used to arrive at $RLOG_a$. The value obtained from the $RLOG_{a_{MON}}$ look-up table is displayed as indicated at step 146. The steps of the monitoring period are repeated until $t_{MON} \geq T_{MON}$ as shown at step 148.

Alternative steps may be substituted to or added to the method of the invention without departing from its intended scope. For example, it is possible to arrive at a calibration factor by comparing the $F(SO_2)_{EP}$ and $F(SO_2)_{NP}$ values to determine what percentage of the SO_{2MON} value represents the S_aO_2 level. However, the above described steps are presently preferred in order to obtain the most

35

-37-

1 accurate S_aO_2 determinations when the photodetection means
is configured to operate in a transmission mode such as is
the case in the embodiment represented in Figure 2.

5 Significantly, the inventive concepts taught herein may
also be carried out by configuring the light emitting means
and the photo detection means to operate in a reflective
mode. A structure adapted for operating in a reflective
mode is represented in Figure 2A which is a cross sectional
10 view showing LED 54A and LED 56A positioned within a
pressure cuff 34A adjacent the photodiode 64A. Positioning
the LEDs 54 and 56A adjacent to the photodiode 64A, or in
another similar position, allows the photodiode 64A to
receive that portion of the light beams reflected from the
blood, tissue, and bone of the patient's finger 36A. It
15 will be appreciated that it is necessary to operate the
embodiment in such a reflective mode to best utilize body
parts such as the patient's forehead as a sensing location.

When an apparatus which embodies the inventive concepts
taught herein is operated in a reflective mode, it is
20 necessary to alter the method set forth in the flow charts
of Figures 3A and 3B somewhat. Thus, the flow chart shown
in Figures 5A and 5B provide the steps carried out when
using the presently preferred structure represented in
Figure 2A.

25 The steps shown in the flow chart of Figures 5A and 5B
closely parallel the steps previously described in
connection with Figures 3A and 3B except where departures
are necessary to allow operation in a reflective mode.
When the photodetector is positioned to receive light which
30 is reflected from the patient's body part, it is necessary
to calculate and store Y_{EP} (rather than $RLOG_{EP}$ when
operating in the transmission mode). A value for Y_{EP} is
derived from the stored average values according to
equation (8) provided below.

35

-38-

$$Y_{EP} = \frac{\Delta V_{R_{EP}}}{\bar{V}_{R_{EP}}} \quad (8)$$

Those skilled in the art will appreciate that the calculation of Y_{EP} , and the other calculations represented in Figures 5A and 5B, may be readily carried out by a microcomputer as previously explained.

Once a value for Y_{EP} is calculated and stored, the S_aO_2 corresponding to the calculated value of Y_{EP} is found by reference to a Y_{EP} look-up table as indicated at step 218A. The Y_{EP} look-up table is derived from empirical data gathered during use of the system described herein. For example, once a red LED, infrared LED, photodiode, and other hardware items have been configured to provide the system described herein, the values obtained for Y_{EP} may be correlated with the S_aO_2 value obtained using another S_aO_2 determination method, for example, an in vitro method. Alternatively, the subject's S_aO_2 may be altered by altering the composition of the inspired gases and monitoring the composition of the expired gases. Once the Y_{EP} look-up table has been completed, it can be used in the case of any number of patients if the performance of the apparatus hardware is maintained within appropriate parameters considering the effects of age, temperature, and variability of mass produced components.

The S_aO_2 which was determined from the Y_{EP} look-up table at step 118A is displayed as represented at step 120A in Figure 5A on the display means 42 represented in Figure 2. It should be appreciated that the S_aO_2 value displayed at step 120A during the enhancement pressure on interval is more accurate and reliable than S_aO_2 values provided by previously available pulse oximetry systems due to the

-39-

1 enhancement of the arterial pulsatile signal output from
the photodiode and the decrease of the capillary oxygen
saturation contribution to the same signal.

5 Nevertheless, as explained previously, the interval
during which the enhancement pressure is imposed must be
limited due to several considerations including avoiding
pain for the patient and affecting the physiology of the
patient so that the measurements obtained are altered in
10 any significant fashion. Thus, the enhancement pressure is
released from the body part for the remainder of the
calibration period and monitoring period as represented at
step 122A as shown in Figure 5B.

As shown in Figure 4, the enhancement pressure-off
interval of the calibration period begins when the
15 enhancement pressure is released and the pressure on the
body part returns to the ambient pressure. Again, as
represented at step 124A, it is necessary to wait at least
two heartbeats before measuring any variables.

Continuing to refer to Figure 5B and similarly to the
20 steps taken during the enhancement pressure-on interval,
the enhancement pressure-off interval includes steps to
determine four variables as shown at step 126A. The same
variables previously defined shown at step 126 in Figure 3B
have the same definition in the flow chart of Figures 5A
25 and 5B when the embodiment operates in a reflective mode.

Also, similarly to the steps taken during the
enhancement pressure-on interval, the average of multiple
determinations of the enhancement pressure-off interval
variables (step 128A) is calculated until the length of the
30 enhancement pressure-off interval (t_{NP}) is equal to or
greater than the time previously set for the enhancement
pressure-off interval (T_{NP}) as represented at step 130A in
Figure 5B.

35

1 As represented in Figure 5B, a value for Y_{NP} is then obtained and stored at step 132A in accordance with equation (9) provided below.

$$5 \quad Y_{NP} = \frac{\Delta V_{R_{NP}} / \bar{V}_{R_{NP}}}{\Delta V_{IR_{NP}} / \bar{V}_{IR_{NP}}} \quad (9)$$

10 Having calculated and stored both Y_{EP} and Y_{NP} , Δ may be calculated according to equation (10).

$$15 \quad \Delta = \frac{Y_{EP}}{Y_{NP} - 1} \quad (10)$$

Since Δ has been calculated in accordance with equation (10), corrections may be made to subsequent S_aO_2 measurements to account for the effect of S_cO_2 and to reduce or eliminate the contribution of S_cO_2 on the S_aO_2 level of the patient to be displayed. Having carried out these steps, the calibration period is complete.

The first step which takes place during the monitoring period (t_{MON}), shown at 136A in Figure 5B, requires that Y_{MON} be calculated according to equation (11) provided below.

$$30 \quad Y_{MON} = \frac{\Delta V_{R_{MON}} / \bar{V}_{R_{MON}}}{\Delta V_{IR_{MON}} / \bar{V}_{IR_{MON}}} (1-\Delta) \quad (11)$$

Next, at step 138A, a running average of Y_{MON} is calculated.

35

-41-

1 Having calculated an average value of Y_{MON} , the S_aO_2
level may be determined by obtaining a value from the Y_{MON}
look-up table as represented at step 144A. The Y_{MON} look-
up table is derived in an empirical fashion similar to the
5 fashion described for the Y_{EP} look-up table. Significantly,
the value obtained from the Y_{MON} look-up table represents
the S_aO_2 value since the S_cO_2 contribution has already been
"calibrated out" in previous steps. The value obtained
from the Y_{MON} look-up table is displayed as represented at
10 step 146A. As shown at step 148A, the steps of the
monitoring period are repeated until $t_{MON} \geq T_{MON}$.

As indicated previously, the system represented in
Figures 2 and 2A includes all the hardware necessary to
carry out blood pressure determinations as described and
15 claimed in United States Patent Application Serial No.
07/068,107 which was previously incorporated herein by
reference.

As set forth in the aforementioned application, two of
the three parameters (mean arterial pressure and systolic
20 arterial pressure) may be measured using the widely known
oscillometric method and the third parameter (diastolic
arterial pressure) may be calculated using a recursive
procedure wherein an estimate of the diastolic pressure is
made and the estimated diastolic pressure, and the other
25 parameters set forth earlier, are used in Hardy model
calculations. If the estimate was correct, the calculated
mean arterial pressure will agree with the measured
arterial pressure. Once all three parameters have been
determined, the Hardy model compliance curve can be used to
30 continuously calculate a blood pressure waveform using the
 V_R signal. It will be appreciated that the signal produced
by the red LED will most accurately reflect volume changes
in the arteries being examined. With the relative changes
in volume being available by examining the V_R signal, the
35

1 pressure-volume relationship of the artery described by the
Hardy model allows the pressure waveform to be calculated.

As in the case of the enhanced pulse oximetry method
described herein, it is necessary to regularly calibrate
5 the values used in the blood pressure determinations due to
changes in the physiology of the patient.

In most cases, it is generally not necessary to conduct
a complete oscillometric determination of both systolic and
mean arterial pressures as often as it is necessary to
10 begin a calibration period for S_aO_2 determinations. Thus,
the period during which the oscillometric determination is
carried out is referred to as a "super calibration period."
It should be understood that the oscillometric method
requires that the artery be completely occluded and thus
15 whatever means which is used to impose the enhancement
pressure on the body part should be capable of imposing
such a pressure. Also, because the pressure imposed is
greater than the systolic pressure, it may require that an
appropriate waiting period be provided before S_aO_2
20 determinations can be reliably made.

Significantly, the enhancement pressure, which equals
the mean arterial pressure, is applied during every
calibration period for S_aO_2 determinations. This allows
the measured mean arterial pressure to be compared to the
25 mean arterial pressure being used in the Hardy model
calculations and, if a significant discrepancy between the
two is found, a super calibration period may be begun.

It will thus be appreciated that the present invention
provides a great advantage in allowing both arterial oxygen
30 and blood pressure determinations to be made using little
more hardware than that which is required for determining
arterial oxygen levels. Also, the present invention is
able to distinguish arterial oxygen saturation levels from
capillary oxygen saturation levels and to provide arterial
35

-43-

1 oxygen saturation level determinations which are more
accurate and reliable than those available from previously
known oximetry systems.

5 The invention may be embodied in other specific forms
without departing from its spirit or essential character-
istics. The described embodiment is to be considered in
all respects only as illustrative and not restrictive. The
scope of the invention is, therefore, indicated by the
appended claims rather than by the foregoing description.
10 All changes which come within the meaning and range of
equivalency of the claims are to be embraced within their
scope.

15

20

25

30

35

-44-

1 What is claimed is:

1. A system for enhancing noninvasive monitoring of a patient's arterial oxygen saturation level, said system comprising:

5 light means for passing at least a first light beam and a second light beam into a body part of said patient containing both arterial and nonarterial blood vessels;

10 detection means for detecting relative amounts of each said light beam absorbed by blood in the blood vessels;

15 enhancement means for increasing the absorption of the light beams by blood in the arterial blood vessels in relation to blood in the nonarterial blood vessels; processor means, electronically coupled to the light means, the detection means and the enhancement means, for coordinating the operation of each said means in relation to one another, and for deriving from the detected relative amounts of each said light beam an arterial oxygen saturation level; and

20 display means, electronically coupled to the processor means, for outputting a visually perceptible indication of the arterial oxygen saturation level.

25 2. A system as defined in claim 1 wherein the light means comprises first and second light-emitting diodes which produce first and second light beams in the visible and infrared light regions, respectively, and wherein the enhancement means comprises a pressure generating device, the pressure generating device being operative to impose a pressure on the body part for at least a part of the time that the light beams are passing into the blood vessels.

35 3. A system as defined in claim 1 wherein the light means comprises a first solid-state device emitting a light

-45-

1 beam having a wavelength in the range from about 600
nanometers to about 725 nanometers and a second solid-state
device emitting a light beam having a wavelength in the
range from about 875 nanometers to about 1,000 nanometers.

5
4. A system as defined in claim 1 wherein the light
means comprises a first light source emitting a light beam
having a first wavelength which is substantially equally
absorbed by oxyhemoglobin and reduced hemoglobin, the light
10 means further comprising a second light source emitting a
light beam having a second wavelength which is absorbed
unequally by oxyhemoglobin and reduced hemoglobin.

15 5. A system as defined in claim 1 wherein the
enhancement means comprises a cylindrical-like pressure
cuff.

20 6. A system as defined in claim 1 wherein the
enhancement means comprises an inflatable pressure
generating device and means for positioning the inflatable
pressure generating device around the patient's body part.

25 7. A system as defined in claim 4 wherein the light
means comprises a first pair of solid state light emitting
devices and a second pair of solid state light emitting
devices, each pair of light emitting devices including an
infrared light emitting source and a red light emitting
source, each pair of the light emitting devices positioned
on the interior of the pressure cuff and wherein the
30 detection means comprises a solid-state photodetection
device positioned on the interior of the pressure cuff.

35

1 8. A system as defined in claim 1 wherein said
enhancement means comprises a pressure imposing device and
means for varying the pressure within the pressure imposing
device.

5

9. A system as defined in claim 7 further comprising
means for sensing the pressure within the pressure imposing
device.

10 10. A system as defined in claim 8 wherein the means for
sensing the pressure comprises a pressure transducer.

11. A system as defined in claim 2 wherein the light
means further comprises:

15 driver means for driving the light emitting diodes;
and

 multiplexing means for selectively connecting the
driver means to one of the light emitting diodes.

12. A system as defined in claim 2 wherein said detection
20 means comprises:

 a semiconductor photodetection device adapted for
providing an output signal proportional to the intensity
of light beams striking the photo detection device;

25 a gain control amplifier adopted for controlling the
gain of the output signal; and

 multiplexing means for directing the output signal
to one of a plurality of channels provided in the
processor means.

30 13. A system as defined in claim 1 wherein the processor
means comprises a microprocessor which controls the
operation of the light means and the enhancement means.

35

1 14. A system as defined in claim 1 further comprising
at least one analog to digital converter adapted to
digitize the signal output from the detection means and
5 input the signal to the microprocessor.

15. A system as defined in claim 1 wherein said system
is also used for monitoring of the patient's arterial blood
pressure waveform, and wherein said system further
comprises:

10 a first electrical signal proportional to the relative
volume of said arterial blood vessels, the first signal
being output by the detection means;

 wherein the enhancement means comprises pressure means,
associated with the light means, for periodically
15 imposing a pressure on the body part;

 pressure transducer means for detecting the pressure
imposed on the body part and for outputting a second
electrical signal proportional to the pressure;
wherein the processor means comprises means for deriving
20 from the first and second electrical signals the
patient's arterial blood pressure waveform; and

 wherein the display means comprises means for
providing a visually perceptible indication of the
arterial pressure waveform in addition to the indication
25 of arterial oxygen saturation level.

16. A monitoring system for enhanced noninvasive
monitoring of a patient's arterial oxygen saturation level,
said system comprising:

30 pressure means for imposing a pressure on a patient's
body part, the pressure means comprising light means for
periodically directing a first light beam and a second
light beam into both capillary and arterial blood
vessels contained in the body part;

35

1 detection means for detecting relative amounts of
each said light beam absorbed by arterial blood within
the body part;

5 processor means, electronically coupled to the
pressure means and the detection means, for (a)
controlling the pressure means so as to cause the
pressure to be imposed on the body part for at least a
portion of the time that the light beams are passing
10 into the body part, and for (b) deriving from the
detected relative amounts of each said light beam an
arterial oxygen saturation level; and

15 display means, electronically coupled to the
processor means, for outputting a visually perceptible
indication of the arterial oxygen saturation level.

17. A monitoring system as defined in claim 16 wherein
the light means comprises a first solid state device
adapted for emitting the first light beam, the first light
beam having a wavelength substantially within the visible
20 red portion of the spectrum.

18. A monitoring system as defined in claim 17 wherein
the light means further comprises a second solid state
device adapted for emitting the second light beam, the
25 second light beam having a wavelength substantially within
the infrared portion of the spectrum.

19. A monitoring system as defined in claim 16 wherein
the detection means comprises a solid state photodetection
30 device.

20. A monitoring system as defined in claim 19 wherein
the photodetection device is positioned on a pressure
imposing surface of the pressure means.

35

1

21. A monitoring system as defined in claim 20 wherein the pressure means comprises a pressure cuff and the photodetection device is positioned substantially opposite
5 from the position of the light means such that the first and second light beams transmitted through the body part are detected by the photodetection device.

22. A monitoring system as defined in claim 20 wherein
10 the photodetection device is positioned to be substantially adjacent the light means such that the first and second light beams reflected from the body part are detected by the photodetection device.

23. A monitoring system as defined in claim 18 further
15 comprising means for time multiplexing the first and the second light beams such that the first and second light beams are alternately directed into the body part.

24. A monitoring system as defined in claim 16 wherein
20 the processor means comprises a microcomputer.

25. A monitoring system as defined in claim 24 further
25 comprising at least one analog to digital converter adapted to digitize the output from the detection means and input it to the microcomputer.

26. A monitoring system as defined in claim 16 wherein
30 the display means comprises a numeric digital display.

27. A monitoring system as defined in claim 16 wherein
the display means comprises a video display.

35

1 28. A monitoring system as defined in claim 16 wherein
the processor means is further for (c) deriving the
patient's blood pressure from the amounts of light detected
by the phototransducer means.

5

29. A monitoring system as defined in claim 28 wherein
the display means comprises means for displaying the
patient's systolic, diastolic, and mean arterial blood
pressures.

10

30. A monitoring system as defined in claim 20 wherein
the pressure means comprises means for shielding the
photodetection device from ambient light.

15

31. A system as defined in claim 16 wherein the pressure
means comprises a cylindrical-like pressure cuff which is
adapted to be positioned on the patient's finger.

32. A system as defined in claim 16 wherein the pressure
20 means comprises a pressure cuff which is adapted to be
positioned on the patient's toe.

33. A system as defined in claim 16 wherein the pressure
means comprises an inflatable pressure generating device
25 and means for positioning the inflatable pressure
generating device on the patient's forehead.

34. A system as defined in claim 28 further comprising
means for sensing the pressure within the pressure means.
30

35. A system as defined in claim 33 wherein the means
for sensing the pressure comprises a pressure transducer.

35

-51-

1 36. A monitoring system for enhanced noninvasive
monitoring of a patient's arterial oxygen saturation level,
the system comprising:

5 pressure means for imposing a pressure on a patient's
body part, the pressure means comprising first light
means and second light means for periodically directing
first and second light beams in the visible red and
infrared light spectra, respectively, into arterial and
10 capillary blood vessels contained in the body part, the
pressure means further comprising transducer means for
detecting relative amounts of the first and second light
beams absorbed by the blood after being directed into
the capillary and arterial blood vessels;

15 processor means, electronically coupled to the
pressure means for (a) controlling the pressure means
so as to cause the pressure to be intermittently imposed
on the body part as the first and second light beams are
passing into the body part, whereby absorption of said
light beams by arterial blood is increased relative to
20 absorption by non-arterial blood, and for (b) deriving
from the detected relative amount of the first and
second light beams absorbed by the arterial blood an
arterial oxygen saturation level; and

25 display means, electronically coupled to the
processor means, for outputting a visually perceptible
indication of the arterial oxygen saturation level.

30 37. A monitoring system as defined in claim 36 wherein
the transducer means comprises means for receiving the
first and second light beams and outputting an electrical
signal proportional to the intensity of the light beams.

35

-52-

1 38. A monitoring system as defined in claim 36 wherein
the transducer means comprises a solid state photoelectric
transducer physically associated with said pressure means.

5 39. A monitoring system as defined in claim 38 wherein
the pressure means further comprises means for shielding
said solid state photoelectric transducer from ambient
light.

10 40. A monitoring system as defined in claim 36 wherein
the pressure means further comprises pressure transducer
means connected to the processor means, and wherein the
processor means is further for (c) deriving from the light
15 detected by the transducer means the patient's systolic and
diastolic blood pressure.

20 41. A monitoring system as defined in claim 40 wherein
the display means includes means for outputting a visually
perceptible indication of the patient's systolic and
diastolic blood pressure.

25 42. A system as defined in claim 36 wherein the pressure
means comprises a cylindrical-like pressure cuff which is
adapted to be positioned on the patient's finger.

30 43. A system as defined in claim 36 wherein the pressure
means comprises a pressure cuff which is adapted to be
positioned on the patient's toe.

35 44. A system as defined in claim 36 wherein the pressure
means comprises an inflatable pressure generating device
and means for positioning the inflatable pressure
generating device on the patient's forehead.

-53-

1 45. A noninvasive monitoring system for providing an indication of both a patient's arterial blood pressures and arterial oxygen saturation level, the system comprising:

5 light means for passing first and second light beams into a body part of the patient containing both arterial and nonarterial blood vessels, the first and second light beams having wavelengths in the visible and infrared portions of the spectrum, respectively;

10 pressure means, for periodically imposing an increased pressure on the body part, said pressure means being associated with said light means and normally nonocclusive in relation to the blood vessels;

15 light detection means for detecting relative amounts of the first and second light beams reflected by and transmitted through arterial blood vessels and for outputting first and second electric signals proportional to the detected amounts of the first and second light beams respectively, at least one of the signals being proportional to relative volume of said arterial blood vessels;

20 pressure detection means for detecting the pressure imposed on the body part by the pressure means and for outputting a third electric signal proportional to the increased pressure;

25 processor means for receiving the first, second and third electric signals, the processor means comprising means for deriving arterial pressures and for deriving an oxygen saturation level from said electric signals; and

30 display means, electronically coupled to the processor means, for outputting visually perceptible indications of the patient's arterial pressure waveform and oxygen saturation level.

35

1 46. A noninvasive monitoring system as defined in claim
45 wherein the pressure means comprises a cylindrical
pressure cuff.

5 47. A noninvasive monitoring system as defined in
claim 45 wherein the light means comprises first and second
light-emitting diodes.

10 48. A noninvasive monitoring system as defined in claim
45 wherein the light means comprises a first light source
emitting light having a first wavelength which is
substantially equally absorbed by both oxyhemoglobin and
reduced hemoglobin, the light means further comprising a
15 second light source having a second wavelength which is
unequally absorbed by oxyhemoglobin and reduced hemoglobin.

20 49. A noninvasive, monitoring method for determining the
arterial oxygen blood saturation level in a patient's body
part containing both arterial and nonarterial blood
vessels, the method comprising the steps of:

(a) directing a first and a second light beam into
the body part, the first and second light beams having
different wavelengths;

25 (b) imposing an enhancement pressure on the body part
so as to substantially increase the compliance of the
arterial vessels contained in the body part thereby
increasing arterial pulses;

30 (c) detecting the relative amounts of the first and
second light beams absorbed by the blood contained in
the arterial vessels; and

(d) determining the arterial oxygen saturation level
in the body part by the detected amounts of the first
and second light beams.

-55-

- 1 50. A noninvasive, monitoring method as defined in claim
49 further comprising the steps of determining the
patient's mean arterial pressure by changing the pressure
imposed on the body part until the modulation of the first
5 light beam by the pulsing of the arterial blood vessels is
maximized and determining the pressure imposed on the body
part at the time the modulation of the first light beam is
maximized.
- 10 51. A noninvasive, monitoring method as defined in claim
49 wherein the step of imposing an enhancement pressure on
the body part comprises the step of imposing a pressure
circumferentially about the patient's finger.
- 15 52. A noninvasive, monitoring method as defined in claim
49 wherein the steps of imposing an enhancement pressure on
the body part comprises the step of imposing a pressure
circumferentially about the patient's toe.
- 20 53. A noninvasive, monitoring method as defined in claim
49 wherein the step of imposing an enhancement pressure on
the body part comprises the step of imposing a pressure
upon the patient's forehead.
- 25 54. A noninvasive, monitoring method as defined in claim
49 wherein the step of directing a first and a second light
beam into the body part comprises the step of alternatively
directing a first light beam having a wavelength in the
visible red region into the body part and directing a
30 second light beam having a wavelength in the infrared
region into the body part.

1 55. A noninvasive, monitoring method as defined in claim
49 wherein the step of detecting the relative amounts of
the first and second light beams absorbed comprises the
step of detecting the relative amounts of the first and
5 second light beams which are reflected from the body part.

56. A noninvasive, monitoring method as defined in claim
49 wherein the step of detecting the relative amounts of
the first and second light beams absorbed comprises the
10 step of detecting the relative amounts of the first and
second light beams which are transmitted through the body
part.

57. A noninvasive, monitoring method as defined in claim
15 49 wherein the step of detecting the relative amounts of
the first and second light beams absorbed by the body part
comprises the steps of:

 positioning at least one photodetector adjacent to
the body part; and
20 outputting a voltage from the photodetector which
is proportional to the amounts of the first and second
light beams which strike the photodetector.

58. A noninvasive, monitoring method as defined in claim
25 57 wherein the step of determining the arterial oxygen
saturation level comprises the step of comparing the value
of the voltage output from the photodetector to the values
contained in an empirically developed look-up table to find
the oxygen saturation level which corresponds to the value
30 of the voltage output.

59. A noninvasive, monitoring method as defined in claim
49 further comprising the step of displaying the arterial
oxygen saturation level.

35

-57-

1

60. A noninvasive method for monitoring a patient's arterial oxygen saturation level, the method comprising the steps of:

5

(a) establishing a calibration interval comprised of the following steps:

10

(1) directing a first light beam and a second light beam into a body part of the patient containing at least one arterial and at least one nonarterial blood vessel, the first light beam having a first wavelength and the second light beam having a different, second wavelength;

15

(2) imposing a first pressure to the body part such that the arterial blood vessel located therein is at least partially unloaded;

(3) detecting the amount of light from the first light beam and from the second light beam which is absorbed by said body part;

20

(4) determining from said detected amount of the first and second light beams the arterial oxygen saturation level in the body part;

(5) releasing the first pressure from the body part;

25

(6) detecting the amount of light from the first light beam and from the second light beam which is absorbed by the body part after the first pressure is released;

30

(7) determining a calibration factor derived from the differences in the amount of the first and second light beams which were detected when the first pressure was applied to, and released from, the body part, the calibration factor representing the contribution of non-arterial blood oxygen saturation

35

-58-

1 to the amount of light which arrives at the
 phototransducer;

 (b) establishing a monitoring interval by continuing
to detect the amount of the first and second light beams
5 which are absorbed by the body part after the
 calibration factor is determined;

 (c) calculating during the monitoring interval the
oxygen saturation level of the arterial blood using the
calibration factor; and

10 (d) displaying the oxygen saturation level on a
visual display.

61. A noninvasive method for monitoring a patient's
arterial oxygen saturation level as defined in claim 60
15 further comprising the step of repeatedly beginning a
calibration interval followed by a monitoring interval.

62. A noninvasive method for monitoring a patient's
arterial oxygen saturation level as defined in claim 60
20 wherein the first pressure is about equal to the patient's
mean arterial pressure.

63. A noninvasive method for monitoring a patient's
arterial oxygen saturation level as defined in claim 60
25 wherein the calibration interval is less than one third the
length of the monitoring interval.

64. A noninvasive method for monitoring a patient's
arterial oxygen saturation level as defined in claim 60
30 wherein the first wavelength is in the infrared portion of
the spectrum and the second wavelength is in the visible
red portion of the spectrum.

-59-

1 65. A noninvasive method for monitoring a patient's
arterial oxygen saturation level as defined in claim 60
further comprising a method for noninvasively monitoring
the patient's blood pressure, the method further comprising
5 the steps of:

 measuring the body part's systolic and mean arterial
pressure using the oscillometric method;
detecting the change in volume of the patient's blood
vessel by the change in intensity of one of the light
10 beams;

 estimating a diastolic pressure;
calculating a mean arterial pressure using the Hardy
model equation which relates arterial volume to arterial
pressure and the estimated diastolic pressure;
15 comparing the calculated mean arterial pressure and the
measured mean arterial pressure;

 estimating the diastolic pressure and recalculating
the mean arterial pressure until the two values agree
within a predetermined standard; and

20 displaying the measured systolic and the most
recently estimated diastolic blood pressure on a visual
display.

25 66. A noninvasive method for monitoring a patient's
arterial oxygen saturation level and blood pressure as
defined in claim 65 further comprising the step of
continually displaying the patient's blood pressure
waveform.

30 67. A noninvasive method for monitoring a patient's
oxygen saturation level as defined in claim 60 wherein the
step of detecting the amount of light from the first light
beam and from the second light beam comprises the step of
detecting the amount of light from the first light beam and
35

-60-

1 from the second light beam which are reflected from the
body part.

5 68. A noninvasive method for monitoring a patient's
oxygen saturation level as defined in claim 60 wherein the
step of detecting the amount of light from the first light
beam and the second light beam comprises the step of
detecting the amount of light from the first light beam and
from the second light beam which are transmitted through
10 the body part.

69. A method for noninvasively determining a patient's
arterial oxygen saturation level, the method comprising the
steps of:

15 (a) imposing an enhancement pressure on a body part
containing both arterial and nonarterial blood vessels
so as to significantly increase the pulsation by the
arterial blood vessels in the body part;

20 (b) directing a first and a second light beam into
the body part, the first and second light beams having
different wavelengths;

(c) detecting the amounts of the first and second
light beams absorbed by the arterial blood;

25 (d) determining the arterial oxygen saturation level
in the body part from the detected amounts of the first
and second light beams;

(e) displaying the arterial oxygen saturation level;

(f) releasing the enhancement pressure from the body
part;

30 (g) detecting the relative amounts of the first and
second light beams absorbed by the arterial and
nonarterial blood in the body part;

(h) determining the relative contribution to said
absorption attributable to the arterial blood with
35

-61-

1 respect to the total of the amount of the first and
second light beams which are detected; and

 (i) displaying an oxygen saturation level
5 corresponding to substantially only the contribution of
the arterial blood to the detected amounts of the first
and second light beams when the enhancement pressure is
removed.

70. A method for noninvasively determining a patient's
10 arterial oxygen saturation level as defined in claim 69
wherein the step of imposing an enhancement pressure on a
body part comprises the step of imposing a pressure
approximately equal to the body part's mean arterial
15 pressure circumferentially about one of the patient's
digits and wherein the step of detecting the amounts of the
first and second light beams absorbed by the arterial blood
comprises the step of detecting with a phototransducer
device the amount of the first and second light beams
transmitted through the patient's digit.

20

71. A method for noninvasively determining a patient's
arterial oxygen saturation level as defined in claim 69
wherein the step of detecting the amounts of the first and
second light beams absorbed by the arterial blood comprises
25 the step of detecting with a phototransducer device the
amount of the first and second light beams reflected from
the body part.

72. A method for noninvasively determining a patient's
30 arterial oxygen saturation level as defined in claim 69
wherein the step of determining the arterial oxygen
saturation level in the body part comprises the step of
comparing the amount of the first and second light beams
which are absorbed with a set of predetermined look-up

35

-62-

1 table values and deriving from the look-up table values an
arterial oxygen saturation level and wherein the step of
displaying the arterial oxygen saturation level comprises
the step of outputting the arterial oxygen saturation level
5 to a visually perceptible display.

73. A method for noninvasively determining a patient's
arterial oxygen saturation level as defined in claim 69
further comprising the step of repeating steps (g) through
10 (h) a multiplicity of times before repeating steps (a)
through (f).

74. A noninvasive method for continuously monitoring a
patient's arterial oxygen saturation and arterial blood
15 pressure waveform, the method comprising:

imposing an occlusive pressure on a patient's body
part containing both arterial and nonarterial blood
vessels;

20 directing at least a first light beam into the body
part;

gradually releasing the occlusive pressure;

detecting when a pulsatile signal first modulates
the first light beam;

25 measuring the occlusive pressure imposed on the body
part when the pulsatile signal first modulates the first
light beam and storing the value of the pressure as the
systolic pressure;

releasing the occlusive pressure;

30 imposing an enhancement pressure on the body part
such that the modulation of the first light beam is
substantially maximized to determine a measured mean
arterial pressure;

estimating an arterial diastolic pressure;

35

-63-

1 calculating a mean arterial pressure using the estimated
diastolic pressure, the measured systolic pressure, the
detected amounts of the first light beam, and a formula
which relates arterial pressure to arterial volume;

5 comparing the calculated mean arterial pressure to
the measured mean arterial pressure and displaying at
least the diastolic pressure if the measured mean
arterial pressure and the calculated arterial pressure
agree within a predetermined standard;

10 directing a second light beam into the body part
while the enhancement pressure is imposed on the first
and second light beams having different wavelengths;

15 detecting the relative amounts of the first and
second light beams absorbed by the arterial blood
contained in the body part;

deriving an arterial oxygen saturation level from
the detected amounts of the first and second light
beams;

20 releasing the enhancement pressure from the body
part;

25 calculating at least a new systolic and diastolic
arterial blood pressure based upon the changes in the
detected amount of the first light beam representing
volume changes in the arteries contained in the body
part while all pressure is released from the body part;

detecting the relative amounts of the first and
second light beams absorbed by the arterial and
nonarterial blood vessels contained in the body part
while all pressure is removed;

30 determining the contribution of the arterial blood
vessels to the detected amount of the first and second
light beam so that the arterial oxygen saturation level
may be determined; and

35

-64-

1 displaying the arterial oxygen saturation level and
the systolic and diastolic arterial blood pressure of
the body part on a visually perceptible display.

5

10

15

20

25

30

35




FIG. 1

2/8




FIG. 2

3/8




FIG. 2A

4/8




FIG. 3A




FIG. 3B

6/8




FIG. 4

7/8




FIG. 5A




FIG. 5B

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/00518

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): A61B 5/02 US Cl.: 128/666																							
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">Classification System</th> <th style="width: 80%;">Classification Symbols</th> </tr> <tr> <td style="text-align: center; vertical-align: top;">U S</td> <td>128/633, 635, 664, 666, 667, 672, 675, 677, 679-683 687-690 356/41</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U S	128/633, 635, 664, 666, 667, 672, 675, 677, 679-683 687-690 356/41																	
Classification System	Classification Symbols																						
U S	128/633, 635, 664, 666, 667, 672, 675, 677, 679-683 687-690 356/41																						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%;">Category *</th> <th style="width: 60%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center;">Y</td> <td>EP, A, 0227 119, 01 July 1987 (NIWA et al) See entire document</td> <td>16-21, 23-27, 30-33, 36-39, 42-44, 49, 51, 54, 56, 57, 59</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 4,846,183, 11 July 1989 (MARTIN) See entire document</td> <td>16-21, 23-27, 30-33, 36-39, 42-44, 49, 51, 54, 56, 57, 59</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 4,759,369, 26 July 1988 (TAYLOR) see column 1 lines 45-68, column 2 lines 1-8 and abstract</td> <td style="text-align: center;">58</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 4,714,080, 22 December 1987 (EDGAR JR. et al) see column 2, lines 39-68 and figure 1</td> <td style="text-align: center;">22, 55</td> </tr> <tr> <td style="text-align: center;">A</td> <td>US, A, 3,412,729, 26 November 1968 (SMITH JR) see column 1, lines 16-29</td> <td>1, 15, 16, 28, 29, 36, 40, 41, 45, 49, 60, 65, 66, 74</td> </tr> <tr> <td style="text-align: center;">A</td> <td>US, A, 4,807,631, 28 February 1989 (HERSH et al) see column 1, lines 37-58</td> <td style="text-align: center;">58</td> </tr> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	EP, A, 0227 119, 01 July 1987 (NIWA et al) See entire document	16-21, 23-27, 30-33, 36-39, 42-44, 49, 51, 54, 56, 57, 59	Y	US, A, 4,846,183, 11 July 1989 (MARTIN) See entire document	16-21, 23-27, 30-33, 36-39, 42-44, 49, 51, 54, 56, 57, 59	Y	US, A, 4,759,369, 26 July 1988 (TAYLOR) see column 1 lines 45-68, column 2 lines 1-8 and abstract	58	Y	US, A, 4,714,080, 22 December 1987 (EDGAR JR. et al) see column 2, lines 39-68 and figure 1	22, 55	A	US, A, 3,412,729, 26 November 1968 (SMITH JR) see column 1, lines 16-29	1, 15, 16, 28, 29, 36, 40, 41, 45, 49, 60, 65, 66, 74	A	US, A, 4,807,631, 28 February 1989 (HERSH et al) see column 1, lines 37-58	58
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																					
Y	EP, A, 0227 119, 01 July 1987 (NIWA et al) See entire document	16-21, 23-27, 30-33, 36-39, 42-44, 49, 51, 54, 56, 57, 59																					
Y	US, A, 4,846,183, 11 July 1989 (MARTIN) See entire document	16-21, 23-27, 30-33, 36-39, 42-44, 49, 51, 54, 56, 57, 59																					
Y	US, A, 4,759,369, 26 July 1988 (TAYLOR) see column 1 lines 45-68, column 2 lines 1-8 and abstract	58																					
Y	US, A, 4,714,080, 22 December 1987 (EDGAR JR. et al) see column 2, lines 39-68 and figure 1	22, 55																					
A	US, A, 3,412,729, 26 November 1968 (SMITH JR) see column 1, lines 16-29	1, 15, 16, 28, 29, 36, 40, 41, 45, 49, 60, 65, 66, 74																					
A	US, A, 4,807,631, 28 February 1989 (HERSH et al) see column 1, lines 37-58	58																					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>																							
IV. CERTIFICATION <table style="width: 100%;"> <tr> <td style="width: 50%;">Date of the Actual Completion of the International Search</td> <td style="width: 50%;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center;">28 June 1990</td> <td style="text-align: center;">04 SEP 1990</td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	28 June 1990	04 SEP 1990																	
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																						
28 June 1990	04 SEP 1990																						
<table style="width: 100%;"> <tr> <td style="width: 50%;">International Searching Authority</td> <td style="width: 50%;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center;">ISA/US</td> <td style="text-align: center;"> Ruth S. Smith </td> </tr> </table>			International Searching Authority	Signature of Authorized Officer	ISA/US	 Ruth S. Smith																	
International Searching Authority	Signature of Authorized Officer																						
ISA/US	 Ruth S. Smith																						
<div style="text-align: right;"> NGUYEN NGOC-HO INTERNATIONAL DIVISION </div>																							